Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, tolerability, and safety of the
investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip
osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2
selective nonsteroidal anti-inflammatory drugs [NSAIDs]).